OPK is a strong drug pipe line and 10 analysts has strong buy with average target price of $30.
There will be upgrades to follow. Trust me!
Their ovarian cancer drug will be file in June for FDA approval and their lung cancer drug will be filed 1qtr of 2016. This will be bought out by a big pharma!
It is done for!